To the Editor Pharmacological treatment of schizophrenia in the real world is frequently challenging. Dr McEvoy and colleagues1 compared paliperidone palmitate with haloperidol decanoate in patients with schizophrenia deemed at high risk of destabilization.
McEvoy et al1 found that paliperidone palmitate was not significantly different from haloperidol decanoate in the rate of efficacy failure (33.8% vs 32.4%, respectively), with some differences in tolerability. Several issues need to be taken into account in interpreting their clinically relevant findings.
Suzuki T. Antipsychotic Medications for Schizophrenia. JAMA. 2014;312(14):1468–1469. doi:10.1001/jama.2014.10103
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: